• Home >
  • Vital Signs - Healthcare News - The Analysts Perspect March 2014 Issue

Vital Signs - Healthcare News - The Analysts Perspect March 2014 Issue

31-Mar-2014  /  Research Code: 9A35-00-12-00-00  /  SKU: LS00215-NA-MR_17480  /  
Region: North America

Regular Price: USD 450.00

Special Price USD 405.00

10% OFF

* Required Fields

Regular Price: USD 450.00

Special Price USD 405.00

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gilead's Sovaldi, Sony's genomic partnership with Illumina, and Craig Venter’s latest venture, Human Longevity, Inc.

Table of Contents

Vital Signs - Healthcare News - The Analyst's Perspect March 2014 IssueVital Signs: March 31 2014This Week's Issue




Keyword1

Keyword2

Keyword3

Related Research

Global Mobility Industry Outlook, 2018

Release Date : 23-Apr-18

Region : North America

Top Trends and Outlook in Health IT—HIMSS18 Conference Report

Release Date : 18-Apr-18

Region : North America

EU GDPR Compliance Deadline Looms: What are Cyber Security Vendors Doing to Prepare Customers?

Release Date : 13-Apr-18

Region : North America

Apple Inc. Performance Tracker, 2018

Release Date : 13-Apr-18

Region : North America

Cloud Communications Providers Boost Portfolios with Contact Center Solutions

Release Date : 12-Apr-18

Region : North America

Why Frost & Sullivan

Vision & Strategy

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Brand & Demand

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Technology & IP

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

Global Prespective

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.